Cancer cells sound an alarm to survive the drug attack
For the roughly half of colorectal cancer patients whose tumors carry a KRAS mutation, the promise of targeted therapy has long been shadowed by a stubborn paradox: the drugs exist, yet resistance arrives swiftly and outcomes remain poor. A new preclinical study from MD Anderson Cancer Center and Weill Cornell Medicine illuminates why — cancer cells escape not through one strategy but two, mutating genetically or quietly reshaping their inner lives without any mutation at all. In mapping this dual evasion, researchers have also found a potential lever to pull: blocking the inflammatory alarm signal that cancer cells use to mount their escape may restore the drug's power, pointing toward a combination therapy worth testing in patients.
- KRAS inhibitors like adagrasib and sotorasib reach only a fraction of eligible colorectal cancer patients, and even those who respond typically relapse quickly — the urgency to understand why is clinical and immediate.
- Cancer cells under drug pressure don't surrender; they either acquire new mutations in bypass pathways or shift their behavioral state entirely, and both escape routes can operate simultaneously within a single tumor.
- The most revealing discovery is timing: the moment a KRAS inhibitor strikes, cancer cells fire an early inflammatory alarm that appears to be the decisive window in which adaptation — and therefore resistance — begins.
- Blocking TBK1, a key node in that inflammatory signaling cascade, re-sensitized resistant cells to KRAS inhibition in laboratory models, suggesting the alarm can be silenced before the escape is complete.
- The findings now await the harder test — clinical trials in patients — where the dual-inhibition strategy must prove both its efficacy and the tolerability of combining two targeted agents.
Colorectal cancer cells, it turns out, are remarkably resourceful survivors. When struck by a KRAS inhibitor, they do not simply yield — some acquire new genetic mutations that reroute their survival signals around the drug, while others, without changing their DNA at all, quietly shift how they behave and express their genes. A preclinical study published in Cancer Cell, led by researchers at UT MD Anderson Cancer Center and Weill Cornell Medicine, has mapped both escape routes in detail and identified a strategy that may close them.
KRAS mutations drive nearly half of all colorectal cancers, yet the two approved inhibitors — adagrasib and sotorasib — benefit only a small fraction of patients who carry them, and responses rarely last. To understand why, Salvador Alonso Martinez and Kevan Chu examined patient tumor samples collected before, during, and after treatment, using single-cell spatial transcriptomics alongside targeted gene sequencing to observe not just mutations but the living behavior of individual cells within the tumor. Resistant organoids grown in the laboratory completed the picture.
What they found was a dual resistance architecture — genetic and non-genetic mechanisms coexisting within the same tumor, meaning no single countermeasure would suffice. More specifically, they identified a critical early moment: when KRAS inhibitors first attack, cancer cells trigger an inflammatory signaling response, a kind of biological alarm that mobilizes their adaptive machinery. It is in this window that the fate of the cell — death or escape — appears to be decided.
Testing a TBK1 inhibitor in preclinical models, the team found that suppressing this inflammatory alarm re-sensitized resistant cells to KRAS inhibition. The combination worked where either drug alone did not. The road to clinical application remains long, and whether the laboratory findings will hold in patients — and whether dual inhibition proves tolerable — is yet to be determined. But the study offers something foundational: a mechanistic explanation for resistance, and a specific target that suggests the escape is not inevitable.
Colorectal cancer cells are far more resourceful than researchers once thought. When hit with a KRAS inhibitor—one of the newer weapons in the oncology arsenal—they don't simply die. Some mutate. Others shift their behavior entirely, adopting new survival strategies that render the drug ineffective. A preclinical study published this week in Cancer Cell, led by teams at UT MD Anderson Cancer Center and Weill Cornell Medicine, has mapped out exactly how this escape happens, and in doing so, identified a potential way to block it.
The KRAS gene is the most frequently mutated cancer driver in colorectal cancer, appearing in roughly half of all cases. Yet despite this prevalence, the two KRAS inhibitors now available—adagrasib and sotorasib—work in only a fraction of patients who carry the mutation. Those who do respond often see their tumors shrink briefly before resistance sets in, and outcomes remain grim. For years, researchers suspected that secondary mutations acquired during treatment might explain the problem, but the picture remained incomplete.
Salvador Alonso Martinez, an assistant professor of gastrointestinal medical oncology at MD Anderson, and Kevan Chu, a graduate student at Weill Cornell, led the investigation by examining patient samples collected before treatment, during treatment, and at the point of disease progression. They used targeted gene sequencing and single-cell spatial transcriptomics—techniques that allow researchers to see not just what genes are mutated, but how individual cells are behaving within the tumor landscape. They also tested laboratory-grown tumor organoids that had developed resistance to KRAS inhibitors.
What emerged was a picture of dual resistance. Some cancer cells, as suspected, acquired new mutations in secondary pathways that allowed them to bypass the KRAS inhibitor's effects. But others took a different route entirely. Without any genetic change, these cells simply altered their functional state—the way they expressed genes and responded to their environment—to survive. Both mechanisms often coexisted within the same tumor, meaning resistance was not a single problem with a single solution.
The researchers discovered something more specific: when KRAS inhibitors first attack the cancer cells, they trigger what amounts to an alarm response. The cells activate inflammatory signaling pathways, essentially calling for help to adapt and endure. This early inflammatory surge appeared to be the critical moment—the window in which cells either die or mount their escape.
Testing a compound called TBK1 inhibitor in their preclinical models, the researchers found that blocking this inflammatory response made cancer cells vulnerable again to KRAS inhibition. In other words, by suppressing the alarm signal, they could prevent the adaptation that leads to resistance. The combination of a KRAS inhibitor plus TBK1 blockade sensitized resistant cells back to treatment, at least in the laboratory setting.
The implication is straightforward: a two-drug approach might succeed where single-agent KRAS inhibition fails. But the path from preclinical discovery to clinical reality is long. The next step will be testing this combination in patients, determining whether the laboratory findings hold up in living tumors, and whether the side effects of dual inhibition are manageable. For now, the study offers something more valuable than a cure—it offers a mechanism, a reason to believe that resistance is not inevitable, and a specific target to aim at.
Citações Notáveis
Resistance does not come from a single source, but from both genetic and non-genetic factors often coexisting in the same tumor— Study findings, published in Cancer Cell
Targeting the adapted early inflammatory response may be the key to stopping resistance and improving the effectiveness of KRAS therapies— Salvador Alonso Martinez, M.D., UT MD Anderson
A Conversa do Hearth Outra perspectiva sobre a história
Why does resistance happen so quickly with these KRAS inhibitors? It seems like they should work better than they do.
The cancer cells are smarter than we gave them credit for. When you hit them with a drug, some acquire new mutations to work around it. But others don't mutate at all—they just change how they behave, like switching to a different survival mode. Both things happen at once in the same tumor.
So you're saying the cancer isn't just evolving genetically. It's also adapting behaviorally.
Exactly. And the behavioral adaptation seems to start with an inflammatory response—the cells essentially sound an alarm that helps them survive the initial drug attack. That's the moment that matters.
If you can block that alarm, what happens?
In the lab, the cancer cells become vulnerable again. They can't adapt, so the KRAS inhibitor can do its job. That's why combining a TBK1 inhibitor with the KRAS drug might work where either one alone fails.
But this is all preclinical. How confident are you that it will work in actual patients?
That's the honest question. We've mapped the mechanism. We know what's happening. Now we need to test it in people and see if the biology holds up in a living tumor, with all its complexity. The mechanism is sound, but medicine is always more complicated than the lab.